These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 10550566)

  • 61. Therapeutic monitoring of continuous infusion etoposide in small-cell lung cancer.
    Joel SP; Ellis P; O'Byrne K; Papamichael D; Hall M; Penson R; Nicholls S; O'Donnell C; Constantinou A; Woodhull J; Nicholson M; Smith I; Talbot D; Slevin M
    J Clin Oncol; 1996 Jun; 14(6):1903-12. PubMed ID: 8656259
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Oral therapy for small cell lung cancer.
    Postmus PE; Smit EF
    Lung Cancer; 1995 Jun; 12 Suppl 3():S63-70. PubMed ID: 7551958
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Prolonged administration of low-daily-dose etoposide: a superior dosing schedule?
    Greco FA; Hainsworth JD
    Cancer Chemother Pharmacol; 1994; 34 Suppl():S101-4. PubMed ID: 8070017
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Chronic daily administration of oral etoposide.
    Greco FA; Johnson DH; Hainsworth JD
    Semin Oncol; 1990 Feb; 17(1 Suppl 2):71-4. PubMed ID: 2154861
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A limited sampling method for estimation of the etoposide area under the curve.
    Strömgren AS; Sørensen BT; Jakobsen P; Jakobsen A
    Cancer Chemother Pharmacol; 1993; 32(3):226-30. PubMed ID: 7684658
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Predicting etoposide toxicity: relationship to organ function and protein binding.
    Joel SP; Shah R; Clark PI; Slevin ML
    J Clin Oncol; 1996 Jan; 14(1):257-67. PubMed ID: 8558207
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Unchanged pharmacokinetics of VP-16-213 (etoposide, NSC 141540) during concomitant administration of doxorubicin and cyclophosphamide.
    van Hoogenhuijze J; Lankelma J; Stam J; Pinedo HM
    Eur J Cancer Clin Oncol; 1987 Jun; 23(6):807-11. PubMed ID: 2820744
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy.
    Postmus PE; Berendsen HH; van Zandwijk N; Splinter TA; Burghouts JT; Bakker W
    Eur J Cancer Clin Oncol; 1987 Sep; 23(9):1409-11. PubMed ID: 2824211
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Treatment of non-small-cell lung cancer with prolonged oral etoposide.
    Kakolyris S; Samonis G; Koukourakis M; Vlachonicolis I; Chalkiadakis G; Kalbakis K; Souglakos I; Agelaki S; Toloudis P; Georgoulias V
    Am J Clin Oncol; 1998 Oct; 21(5):505-8. PubMed ID: 9781610
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Chronic oral etoposide in the treatment of lung cancer.
    DeVore R; Hainsworth J; Greco FA; Hande K; Johnson D
    Semin Oncol; 1992 Dec; 19(6 Suppl 14):28-35. PubMed ID: 1336897
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Potential cost savings of oral versus intravenous etoposide in the treatment of small cell lung cancer.
    Pashko S; Johnson DH
    Pharmacoeconomics; 1992 Apr; 1(4):293-7. PubMed ID: 10147019
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Phase I trial of aggressive weekly chemotherapy in small-cell carcinoma of the lung.
    Williamson SK; Taylor SA
    Am J Clin Oncol; 1987 Dec; 10(6):496-8. PubMed ID: 2825507
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Pharmacokinetic optimisation of treatment with oral etoposide.
    Toffoli G; Corona G; Basso B; Boiocchi M
    Clin Pharmacokinet; 2004; 43(7):441-66. PubMed ID: 15139794
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer.
    Robison NJ; Campigotto F; Chi SN; Manley PE; Turner CD; Zimmerman MA; Chordas CA; Werger AM; Allen JC; Goldman S; Rubin JB; Isakoff MS; Pan WJ; Khatib ZA; Comito MA; Bendel AE; Pietrantonio JB; Kondrat L; Hubbs SM; Neuberg DS; Kieran MW
    Pediatr Blood Cancer; 2014 Apr; 61(4):636-42. PubMed ID: 24123865
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Phase II study of oral VP-16-213 in small cell lung cancer.
    Matsui Y; Oshima S; Kado M; Nakayama M; Shimokata K; Sakai S; Ito F; Chikata E; Hara K; Kanda T
    Cancer; 1987 Dec; 60(12):2882-5. PubMed ID: 2824017
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Developments in therapy for extensive-disease small cell lung cancer.
    Comis RL
    Semin Oncol; 1992 Dec; 19(6 Suppl 13):45-50. PubMed ID: 1337220
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Does chemotherapy-induced leukopenia predict a response in small-cell lung cancer?
    Jereczek-Fossa B; Jassem J; Karnicka-Młodkowska H; Badzio A; Moś-Antkowaik R; Krawczyk K; Kowal E; Pilarska-Machowicz A; Radzikowska E; Malak K
    J Cancer Res Clin Oncol; 1998; 124(2):106-12. PubMed ID: 9654193
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Pharmacodynamic profile of prolonged etoposide administration in patients with small cell lung cancer and non-Hodgkin's lymphoma.
    Higa GM; Sarkar MA; DeVore RF
    Pharmacotherapy; 1999 Jan; 19(1):101-7. PubMed ID: 9917083
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Intensive chemotherapy in small cell lung cancer.
    Sculier JP; Klastersky J
    Eur J Cancer Clin Oncol; 1986 Dec; 22(12):1417-20. PubMed ID: 3036532
    [No Abstract]   [Full Text] [Related]  

  • 80. Long-term oral etoposide in metastatic breast cancer: clinical and pharmacokinetic results.
    Calvert AH; Lind MJ; Millward MM; Cantwell BM; Gumbrell L; Proctor M; Simmons D; Chapman F; Robinson A; Charlton C
    Cancer Treat Rev; 1993; 19 Suppl C():27-33. PubMed ID: 8221713
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.